Therapeutic approach to Alzheimer's disease: current treatments and new perspectives
T Pardo-Moreno, A González-Acedo… - Pharmaceutics, 2022 - mdpi.com
Alzheimer's disease (AD) is the most common cause of dementia. The pathophysiology of
this disease is characterized by the accumulation of amyloid-β, leading to the formation of …
this disease is characterized by the accumulation of amyloid-β, leading to the formation of …
Designing the next-generation clinical care pathway for Alzheimer's disease
The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct
has facilitated the development of biomarker-guided, pathway-based targeted therapies …
has facilitated the development of biomarker-guided, pathway-based targeted therapies …
Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative disease that is of high importance to the
neuroscience world, yet the complex pathogenicity is not fully understood. Inflammation is …
neuroscience world, yet the complex pathogenicity is not fully understood. Inflammation is …
GFAP as a potential biomarker for Alzheimer's disease: a systematic review and meta-analysis
KY Kim, KY Shin, KA Chang - Cells, 2023 - mdpi.com
Blood biomarkers have been considered tools for the diagnosis, prognosis, and monitoring
of Alzheimer's disease (AD). Although amyloid-β peptide (Aβ) and tau are primarily blood …
of Alzheimer's disease (AD). Although amyloid-β peptide (Aβ) and tau are primarily blood …
Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention
YAR Mahaman, KS Embaye, F Huang, L Li, F Zhu… - Ageing research …, 2022 - Elsevier
Abstract Alzheimer's disease (AD), being the number one in terms of dementia burden, is an
insidious age-related neurodegenerative disease and is presently considered a global …
insidious age-related neurodegenerative disease and is presently considered a global …
Advances in develo** novel therapeutic strategies for Alzheimer's disease
J Cao, J Hou, J **, D Cai - Molecular neurodegeneration, 2018 - Springer
Abstract Alzheimer's Disease (AD), the most prevalent neurodegenerative disease of aging,
affects one in eight older Americans. Nearly all drug treatments tested for AD today have …
affects one in eight older Americans. Nearly all drug treatments tested for AD today have …
Gut–brain axis as a pathological and therapeutic target for neurodegenerative disorders
ARL Toledo, GR Monroy, FE Salazar, JY Lee… - International journal of …, 2022 - mdpi.com
Human lifestyle and dietary behaviors contribute to disease onset and progression.
Neurodegenerative diseases (NDDs), considered multifactorial disorders, have been …
Neurodegenerative diseases (NDDs), considered multifactorial disorders, have been …
Early detection of cognitive decline using machine learning algorithm and cognitive ability test
Elderly people are the assets of the country and the government can ensure their peaceful
and healthier life. Life expectancy of individuals has expanded with technological …
and healthier life. Life expectancy of individuals has expanded with technological …
Blood-based biomarkers for Alzheimer's disease diagnosis and progression: an overview
A Varesi, A Carrara, VG Pires, V Floris, E Pierella… - Cells, 2022 - mdpi.com
Alzheimer's Disease (AD) is a progressive neurodegenerative disease characterized by
amyloid-β (Aβ) plaque deposition and neurofibrillary tangle accumulation in the brain …
amyloid-β (Aβ) plaque deposition and neurofibrillary tangle accumulation in the brain …
Do post-translational modifications influence protein aggregation in neurodegenerative diseases: a systematic review
LN Schaffert, WG Carter - Brain sciences, 2020 - mdpi.com
The accumulation of abnormal protein aggregates represents a universal hallmark of
neurodegenerative diseases (NDDs). Post-translational modifications (PTMs) regulate …
neurodegenerative diseases (NDDs). Post-translational modifications (PTMs) regulate …